Skip to main content
SpringerLink
Log in

Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

Non-alcoholic fatty liver disease (NAFLD) is an insidious pathologic condition that can manifest from simple steatosis to steatohepatitis (NASH) with potential progression to cirrhosis. Like the polycystic ovary syndrome (PCOS), NAFLD is associated with obesity, diabetes mellitus, insulin resistance and metabolic syndrome. PCOS women have an increased risk of NAFLD, but it is debatable which features of PCOS, either specific (androgen excess) or unspecific (metabolic derangements) affect the NAFLD risk.

Methods

We performed a systematic review and meta-analysis of studies that addressed the association of PCOS and NAFLD. We selected 17 studies published between 2007 and 2017 that included 2734 PCOS patients and 2561 controls of similar age and body mass index (BMI).

Results

PCOS patients have increased prevalence of NAFLD (odds ratio 2.54, 95% confidence interval 2.19–2.95). PCOS women with hyperandrogenism (classic phenotype) have a higher prevalence of NAFLD compared to women with PCOS without hyperandrogenism, even after correction for confounding variables. Among women with PCOS, those with NAFLD have higher serum total testosterone (mean difference 0.40 nmol/L, 95% CI 0.29–0.50 nmol/L) and free androgen index (mean difference 4.46, 95% CI 3.53–5.39) than those without NAFLD. The studies that used multivariate analysis controlling for age, BMI, triglycerides, and insulin resistance index confirmed that serum androgens are independent predictors of NAFLD in women with PCOS.

Conclusion

The prevalence of NAFLD is increased in women with PCOS and the presence of NAFLD is associated with high serum androgen levels, in addition to obesity and insulin resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Corrado RL, Torres DM, Harrison SA (2014) Review of treatment options for nonalcoholic fatty liver disease. Med Clin N Am 98:55–72. doi:10.1016/j.mcna.2013.09.001

    Article  PubMed  Google Scholar 

  2. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285. doi:10.1111/j.1365-2036.2011.04724.x

    Article  CAS  PubMed  Google Scholar 

  3. Mishra A, Younossi ZM (2012) Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol 2:135–144. doi:10.1016/s0973-6883(12)60102-9

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28:339–350. doi:10.1055/s-0028-1091978

    Article  PubMed  Google Scholar 

  5. Chen MJ, Ho HN (2016) Hepatic manifestations of women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. doi:10.1016/j.bpobgyn.2016.03.003

    Google Scholar 

  6. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C, Violi F (2005) Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90:1578–1582. doi:10.1210/jc.2004-1024

    Article  CAS  PubMed  Google Scholar 

  7. Vonghia L, Francque S (2015) Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: pathology and beyond. World J Hepatol 7:1905–1912. doi:10.4254/wjh.v7.i15.1905

    Article  PubMed  PubMed Central  Google Scholar 

  8. Xu L, Kitade H, Ni Y, Ota T (2015) Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules 5:1563–1579. doi:10.3390/biom5031563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bieghs V, Trautwein C (2014) Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr 3:377–385. doi:10.3978/j.issn.2304-3881.2014.12.04

    PubMed  PubMed Central  Google Scholar 

  10. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121:2111–2117. doi:10.1172/jci57132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Federico A, D’Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, De Palma R (2010) Fat: a matter of disturbance for the immune system. World J Gastroenterol 16:4762–4772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Targher G, Lonardo A, Rossini M (2015) Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest 38:817–825. doi:10.1007/s40618-015-0315-6

    Article  CAS  PubMed  Google Scholar 

  13. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592–1609. doi:10.1053/j.gastro.2012.04.001

    Article  PubMed  Google Scholar 

  14. Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day CP, Loria P (2012) Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 32:1242–1252. doi:10.1111/j.1478-3231.2012.02804.x

    Article  CAS  PubMed  Google Scholar 

  15. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54:1082–1090. doi:10.1002/hep.24452

    Article  PubMed  PubMed Central  Google Scholar 

  16. Siegelman ES, Rosen MA (2001) Imaging of hepatic steatosis. Semin Liver Dis 21:71–80

    Article  CAS  PubMed  Google Scholar 

  17. Yang PM, Huang GT, Lin JT, Sheu JC, Lai MY, Su IJ, Hsu HC, Chen DS, Wang TH, Sung JL (1988) Ultrasonography in the diagnosis of benign diffuse parenchymal liver diseases: a prospective study. Taiwan Yi Xue Hui Za Zhi 87:966–977

    CAS  PubMed  Google Scholar 

  18. McCartney CR, Marshall JC (2016) CLINICAL PRACTICE. Polycystic ovary syndrome. N Engl J Med 375:54–64. doi:10.1056/NEJMcp1514916

    Article  PubMed  PubMed Central  Google Scholar 

  19. Spritzer PM, Lecke SB, Satler F, Morsch DM (2015) Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 149:R219–227. doi:10.1530/rep-14-0435

    Article  CAS  PubMed  Google Scholar 

  20. Cakiroglu Y, Vural F, Vural B (2016) The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J Endocrinol Invest 39:899–907. doi:10.1007/s40618-016-0446-4

    Article  CAS  PubMed  Google Scholar 

  21. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F (2016) Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 14:38. doi:10.1186/s12958-016-0173-x

    Article  PubMed  PubMed Central  Google Scholar 

  22. Durmus U, Duran C, Ecirli S (2017) Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest 40:487–497. doi:10.1007/s40618-016-0582-x

    Article  CAS  PubMed  Google Scholar 

  23. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of intervention. Version 5.1.0. The Cochrane Collaboration (updated March 2011)

  24. Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. doi:10.1186/1471-2288-14-135

    Article  PubMed  PubMed Central  Google Scholar 

  25. Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA (2015) Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol 52:117–123. doi:10.1590/S0004-28032015000200008

    Article  PubMed  Google Scholar 

  26. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N (2010) Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9:402–409

    PubMed  Google Scholar 

  27. Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM (2011) Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 46:479–484. doi:10.3109/00365521.2010.539251

    Article  PubMed  Google Scholar 

  28. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M (2007) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47:412–417. doi:10.1016/j.jhep.2007.04.012

    Article  CAS  PubMed  Google Scholar 

  29. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W (2007) Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5:496–501. doi:10.1016/j.cgh.2006.10.010

    Article  PubMed  Google Scholar 

  30. Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN (2010) Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 95:3332–3341. doi:10.1210/jc.2009-2698

    Article  CAS  PubMed  Google Scholar 

  31. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I (2010) Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25:212–220. doi:10.1093/humrep/dep380

    Article  CAS  PubMed  Google Scholar 

  32. Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G (2010) Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 93:1220–1226. doi:10.1016/j.fertnstert.2008.12.008

    Article  CAS  PubMed  Google Scholar 

  33. Zueff LF, Martins WP, Vieira CS, Ferriani RA (2012) Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 39:341–347. doi:10.1002/uog.10084

    Article  CAS  PubMed  Google Scholar 

  34. Zheng RH, Ding CF (2008) Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study. Zhonghua Fu Chan Ke Za Zhi 43:98–101

    PubMed  Google Scholar 

  35. Qu ZY, Shi YH, Zhao DN, Jiang JJ, Ma ZX, Chen ZJ (2010) Effect of obesity on nonalcoholic fatty liver disease in Chinese women with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 90:2036–2039

    PubMed  Google Scholar 

  36. Polyzos SA, Goulis DG, Kountouras J, Mintziori G, Chatzis P, Papadakis E, Katsikis I, Panidis D (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones (Athens) 13:519–531. doi:10.14310/horm.2002.1493

    Google Scholar 

  37. Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, Andrić Z, Panidis D (2016) Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 31:1347–1353. doi:10.1093/humrep/dew076

    Article  CAS  PubMed  Google Scholar 

  38. Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G (2013) Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci 6:9–14. doi:10.4103/0974-1208.112370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, Kuliczkowska-Płaksej J, Łaczmański Ł, Zaleska-Dorobisz U, Milewicz A (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome—Clinical and metabolic aspects and lipoprotein lipase gene polymorphism. Endokrynologia Polska 65:416–421. doi:10.5603/EP.2014.0058

    Article  PubMed  Google Scholar 

  40. Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, Sloboda DM, Olynyk JK, Hart R (2016) Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. J Gastroenterol Hepatol 31:980–987. doi:10.1111/jgh.13241

    Article  CAS  PubMed  Google Scholar 

  41. Srinivas-Prasad RH, Balakrishna BV, Kudva N, Sandhya H, Ramakrishna P (2014) Incidence of non-alcoholic hepatic fatty infiltration in women with polycystic ovary syndrome. J Evid Med Healthc 1:867–875

    Google Scholar 

  42. Tarantino G, Di Somma C, Pizza G, Brancato V, Nedi V, Valentino R, Orio F, Pivonello C, Colao A, Savastano S (2013) Polycystic ovary syndrome and hepatic steatosis: could low-grade chronic inflammation be mediated by the spleen? Eur J Inflamm 11:179–191

    Article  CAS  Google Scholar 

  43. Jie C, Chunhua W, Yi Z, Yuying W, Wendi X, Tzuchun L, Shengxian L, Lihua W, Jun Z, Yun S, Wei L, Tao T (2017) High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. Int J Obes (Lond). doi:10.1038/ijo.2017.116

    Google Scholar 

  44. Kim JJ, Kim D, Yim JY, Kang JH, Han KH, Kim SM, Hwang KR, Ku SY, Suh CS, Kim SH, Choi YM (2017) Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther 45:1403–1412. doi:10.1111/apt.14058

    Article  CAS  PubMed  Google Scholar 

  45. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD (2010) Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 26:39–46. doi:10.3109/09513590903184084

    Article  CAS  PubMed  Google Scholar 

  46. Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ (2012) Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 97:3709–3716. doi:10.1210/jc.2012-1382

    Article  CAS  PubMed  Google Scholar 

  47. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E (2009) In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 8:199–206

    Article  Google Scholar 

  48. Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2013) Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98:1254–1263. doi:10.1210/jc.2012-3698

    Article  CAS  PubMed  Google Scholar 

  49. Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM (2014) Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon 14:e23235. doi:10.5812/hepatmon.23235

    Article  PubMed  PubMed Central  Google Scholar 

  50. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935. doi:10.1210/jc.2004-1045

    Article  CAS  PubMed  Google Scholar 

  51. Daskalopoulos G, Karkanaki A, Piouka A, Prapas N, Panidis D, Gkeleris P, Athyros VG (2015) Excess metabolic and cardiovascular risk is not manifested in all phenotypes of polycystic ovary syndrome: implications for diagnosis and treatment. Curr Vasc Pharmacol 13:788–800

    Article  CAS  PubMed  Google Scholar 

  52. Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL (2014) A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 80:843–849. doi:10.1111/cen.12258

    Article  CAS  Google Scholar 

  53. Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A (2010) Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95:343–348. doi:10.1210/jc.2009-1834

    Article  CAS  PubMed  Google Scholar 

  54. Kelley CE, Brown AJ, Diehl AM, Setji TL (2014) Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 20:14172–14184. doi:10.3748/wjg.v20.i39.14172

    Article  PubMed  PubMed Central  Google Scholar 

  55. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367–378. doi:10.1053/j.gastro.2015.04.005

    Article  PubMed  Google Scholar 

  56. Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL (2014) Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 81:523–528. doi:10.1111/cen.12369

    Article  CAS  Google Scholar 

  57. Aubuchon M, Kunselman AR, Schlaff WD, Diamond MP, Coutifaris C, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Legro RS (2011) Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96:E1645–1649. doi:10.1210/jc.2011-1093

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Legro RS (2012) Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 30:496–506. doi:10.1055/s-0032-1328878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Research in the authors’ laboratory is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) through the National Institute of Hormones and Women’s Health (Grant # 573747/2008-3).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

    A. L. L. Rocha, G. V. Moreira & F. M. Reis

  2. Department of Internal Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

    L. C. Faria, T. C. M. Guimarães, A. L. Cândido & C. A. Couto

  3. Division of Human Reproduction, Departments of Obstetrics and Gynecology, Hospital das Clínicas, Universidade Federal de Minas Gerais, Av. Alfredo Balena, 110, 9˚ andar, Belo Horizonte, MG, 30130-100, Brazil

    F. M. Reis

Authors
  1. A. L. L. Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. C. Faria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. C. M. Guimarães
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. V. Moreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. L. Cândido
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. A. Couto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. M. Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. M. Reis.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human subjects performed by any of the authors.

Informed consent

No informed consent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rocha, A.L.L., Faria, L.C., Guimarães, T.C.M. et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest 40, 1279–1288 (2017). https://doi.org/10.1007/s40618-017-0708-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-017-0708-9

Keywords

Search

Navigation